Parnassus Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Parnassus Investments’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.5M	Sell	95,378 -2,117	-2%	-$1.44M	0.16%	78
2026 Q1	$75.3M	Buy	97,495 +950	+1%	+$727K	0.22%	64
2025 Q4	$74.5M	Sell	96,545 -4,478	-4%	-$3.04M	0.19%	72
2025 Q3	$56.8M	Sell	101,023 -61	-0.1%	-$34.5K	0.13%	89
2025 Q2	$53.1M	Buy	+101,084	New	+$56.4M	0.12%	91
2020 Q1	–	Sell	-145,000	Closed	-$54.4M	–	109
2019 Q4	$54.4M	Sell	145,000 -480,000	-77%	-$161M	0.18%	79
2019 Q3	$173M	Hold	625,000	–	–	0.63%	47
2019 Q2	$196M	Buy	625,000 +465,000	+291%	+$155M	0.74%	45
2019 Q1	$65.7M	Buy	+160,000	New	+$65.9M	0.26%	67

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Parnassus Investments's REGN Position: Q2 2026 in Review

Parnassus Investments reduced its Regeneron Pharmaceuticals (REGN) stake by 2.2% in Q2 2026, selling an estimated $1.44M and leaving 95,378 shares worth $59.5M. The position accounts for 0.16% of the portfolio, ranked #78.

Parnassus Investments first reported a position in REGN in Q1 2019 and has held it in 9 quarters since. The position peaked at $196M in Q2 2019. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Parnassus Investments held 95,378 shares of Regeneron Pharmaceuticals worth $59.5M as of Q2 2026.
Parnassus Investments sold 2,117 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
Regeneron Pharmaceuticals made up 0.16% of Parnassus Investments's portfolio in Q2 2026, its #78 holding.
Parnassus Investments first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 9 quarters since.
Parnassus Investments's Regeneron Pharmaceuticals position peaked at $196M in Q2 2019.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Parnassus Investments's 13F filing for Q2 2026, filed 29 Jul 2026.